n°107

June 2010

Issue Contents
Editorial

Free  Independence is essential

p.100
A prerequisite for establishing trust

Marketing Authorisations

Sapropterin (phenylketonuria) (New Drug)

p.101-104
For a minority of patients

Sevelamer carbonate (phosphate binder) (New Drug)

p.104-105
No better than sevelamer hydrochloride

Triptorelin (sexual deviations) (New Indication)

p.105
Limited clinical data

Degarelix (prostate cancer) (New Drug)

p.106-108
More rapid castration and nothing more

Liraglutide (type 2 diabetes) (New Drug)

p.109-112
More prudent to continue using exenatide

INN common stems: -vaptan

p.112

INN common stems: -relix

p.112

Gefitinib (non-small cell lung cancer) (New Drug)

p.113
Still no convincing results

Long-acting injectable olanzapine (schizophrenia) (Line Extension)

p.114
Not acceptable

Ezetimibe (primary hypercholesterolaemia) (New Rating)

p.115
No proven benefits

Adverse Effects

Drug-induced myopia, hyperopia and accommodation disorders

p.116-119
Usually bilateral and reversible

Free  Neuropsychological effects of macrolides

p.119
Telithromycin effects especially severe

Postmenopausal hormone replacement therapy and meningioma

p.120
To be weighed in the balance

Cyproterone too

p.120

Lung cancer associated with beta-carotene supplementation in smokers

p.121
A meta-analysis contradicting previous data

Free  Benfluorex: yet more valve disorders

p.121
Suspended from the French market

Inhaled antimuscarinic drugs: cardiovascular toxicity

p.122-123
Consistent and worrying data

Psoriasis due to TNF alpha antagonists

p.123
Paradoxical effects

Salicylate oral gel: Reye's syndrome

p.123
A few cases in children

Adverse effects of papillomavirus vaccination: 2009 data

p.124
Nothing new

Ezetimibe

p.124
Excess cancer incidence

Macular oedema linked to latanoprost and rosiglitazone

p.125
Visual disorders

Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders

p.125
Adverse effects piling up

Lenalidomide: Stevens-Johnson syndrome

p.125
Withdraw promptly at first signs

Sibutramine: cardiovascular events

p.125
Do not use

Reviews

Automated external defibrillation by first-responders

p.126-129
Slightly fewer deaths from ventricular fibrillation

INR self-monitoring and oral anticoagulants

p.130-132
Helpful to some patients

Gestational diabetes

p.133-134
Too many uncertainties to recommend routine screening

Artesunate suppositories

p.134
An option for severe malaria

Outlook

Free  Drug packaging in 2009: a few advances

p.135-137

Free  The finances of Association Mieux Prescrire: 2009 Prescrire annual report

p.138-139

Drug companies monitor prescriptions and sales to fine-tune their marketing strategies

p.140-141

Free  Pharmacovigilance: an opportunity for the European Commission to put patients' interests first

p.141

Free  Direct-to-consumer advertising: the European Commission's plan

p.142

Free  Who finances Prescrire's activities?

p.144

Masthead

Free  Masthead

p.98

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe